Evidence map›Paper›PMID 21251264›Full record

ArticleBMC gastroenterology2011

Computational prediction and experimental validation associating FABP-1 and pancreatic adenocarcinoma with diabetes.

Ravi N Sharaf, Atul J Butte, Kelli D Montgomery, Reetesh Pai, Joel T Dudley, Pankaj J Pasricha

Open access · goldAbstract readValidation Study
In one paragraph

Article in BMC gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Open data informatics and data repurposing for IBD.Nature reviews. Gastroenterology & hepatology · 2018
    Article
  8. Article
  9. Fatty acid-binding protein 1 is preferentially lost in microsatellite instable colorectal carcinomas and is immune modulated via the interferon γ pathway.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017
    Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ravi N SharafDepartment of Gastroenterology and Hepatology, Stanford University School of Medicine, Alway Building, Room M211, 300 Pasteur Drive, MC: 5187, Stanford, CA 94305-5187, USA. rsharaf@stanford.edu
Atul J Butte
Kelli D Montgomery
Reetesh Pai
Joel T Dudley
Pankaj J Pasricha
Stanford University · USLucile Packard Children's Hospital · US

Funding

Repositioning drugs for the treatment of small cell lung cancerR01GM079719 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BUTTE, ATUL J · 2006 to 2015
$4.4M
NIGMS NIH HHS R01 GM079719
6 · The paper itself

Abstract

backgroundPancreatic cancer, composed principally of pancreatic adenocarcinoma (PaC), is the fourth leading cause of cancer death in the United States. PaC-associated diabetes may be a marker of early disease. We sought to identify molecules associated with PaC and PaC with diabetes (PaC-DM) using a novel translational bioinformatics approach. We identified fatty acid binding protein-1 (FABP-1) as one of several candidates. The primary aim of this pilot study was to experimentally validate the predicted association between FABP-1 with PaC and PaC with diabetes.

methodsWe searched public microarray measurements for genes that were specifically highly expressed in PaC. We then filtered for proteins with known involvement in diabetes. Validation of FABP-1 was performed via antibody immunohistochemistry on formalin-fixed paraffin embedded pancreatic tissue microarrays (FFPE TMA). FFPE TMA were constructed using 148 cores of pancreatic tissue from 134 patients collected between 1995 and 2002 from patients who underwent pancreatic surgery. Primary analysis was performed on 21 normal and 60 pancreatic adenocarcinoma samples, stratified for diabetes. Clinical data on samples was obtained via retrospective chart review. Serial sections were cut per standard protocol. Antibody staining was graded by an experienced pathologist on a scale of 0-3. Bivariate and multivariate analyses were conducted to assess FABP-1 staining and clinical characteristics.

resultsNormal samples were significantly more likely to come from younger patients. PaC samples were significantly more likely to stain for FABP-1, when FABP-1 staining was considered a binary variable. Compared to normals, there was significantly increased staining in diabetic PaC samples (p = 0.004) and there was a trend towards increased staining in the non-diabetic PaC group (p = 0.07). In logistic regression modeling, FABP-1 staining was significantly associated with diagnosis of PaC (OR 8.6 95% CI 1.1-68, p = 0.04), though age was a confounder.

conclusionsCompared to normal controls, there was a significant positive association between FABP-1 staining and PaC on FFPE-TMA, strengthened by the presence of diabetes. Further studies with closely phenotyped patient samples are required to understand the true relationship between FABP-1, PaC and PaC-associated diabetes. A translational bioinformatics approach has potential to identify novel disease associations and potential biomarkers in gastroenterology.

Indexed as

Computational BiologyAdenocarcinomaAdultAgedDiabetes ComplicationsDiabetes MellitusFatty Acid-Binding ProteinsFemaleGenomicsHumansImmunohistochemistryLogistic ModelsMaleMiddle AgedPancreatic NeoplasmsPilot ProjectsFABP1 protein, humanFatty Acid-Binding Proteins

Identifiers

PMID21251264
PMCPMC3037918
OpenAlexW2152032833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.